Neumora Therapeutics Inc [NMRA] stock is trading at $0.9, up 8.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NMRA shares have gain 18.29% over the last week, with a monthly amount glided 13.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on April 02, 2025, when BofA Securities downgraded its rating to a Underperform but kept the price target unchanged to $1 for it. Previously, William Blair downgraded its rating to Mkt Perform on March 10, 2025. On March 07, 2025, downgrade downgraded it’s rating to Hold and revised its price target to $2 on the stock. Guggenheim downgraded its rating to a Neutral. RBC Capital Mkts downgraded its rating to a Sector Perform and reduced its price target to $4 on January 02, 2025. JP Morgan downgraded its rating to Neutral for this stock on November 05, 2024, and downed its price target to $15. In a note dated October 01, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $30 on this stock.
Neumora Therapeutics Inc [NMRA] stock has fluctuated between $0.61 and $17.19 over the past year. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $0.9 at the most recent close of the market. An investor can expect a potential return of 122.22% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.01, Equity is -0.85 and Total Capital is -1.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8132 points at the first support level, and at 0.7311 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9553, and for the 2nd resistance point, it is at 1.0153.
Ratios To Look Out For
For context, Neumora Therapeutics Inc’s Current Ratio is 8.98. As well, the Quick Ratio is 8.98, while the Cash Ratio is 4.47.
Transactions by insiders
Recent insider trading involved Henry Gosebruch, Officer, that happened on Mar 12 ’25 when 15000.0 shares were purchased., BERNS PAUL L completed a deal on Feb 18 ’25 to sell 13871.0 shares. Meanwhile, Milligan Michael Lee sold 1978.0 shares on Feb 18 ’25.
